Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC
Journal of Thoracic Oncology · 2024-10 · 19 (10) · 1427-1437
DOI: 10.1016/j.jtho.2024.06.024 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Thoracic Oncology, 2024-10. Verfasst von Soyeong Jun und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Stanford University, Stanford, California; Stanford Cancer Institute, Stanford University, Stanford, California. Hauptthemen laut MEDLINE: Circulating Tumor DNA, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCI.
Abstract (Originalsprache)
INTRODUCTION: The current standard of care for patients with inoperable stage III non-small cell lung cancer includes chemoradiotherapy (CRT) followed by 1 year of checkpoint inhibitor (CPI) therapy. Nevertheless, the optimal duration of consolidation CPI remains unknown. Here, we characterized the relationship between circulating tumor DNA (ctDNA) minimal residual disease (MRD) and clinical outcomes of patients with unresectable locally advanced non-small cell lung cancer treated on a phase 2 trial of short-course consolidation immunotherapy after CRT, with the goal of testing whether ctDNA may be able to identify patients who do not require a full year of treatment. METHODS: Plasma samples for ctDNA analysis were collected from patients on the Big Ten Cancer Research Consortium LUN 16-081 trial after completion of CRT, before day 1 of cycle 2 (C2D1) of CPI (i.e., 1 mo after treatment start), and at the end of up to 6 months of treatment. Tumor-informed ctDNA MRD analysis was performed using cancer personalized profiling by deep sequencing. Levels of ctDNA at each time point were correlated with clinical outcomes. RESULTS: Detection of ctDNA predicted significantly inferior progression-free survival after completion of CRT (24-mo 29% versus 65%, p = 0.0048), before C2D1 of CPI (24-mo 0% versus 72%, p < 0.0001) and at the end of CPI (24-mo 15% versus 67%, p = 0.0011). In addition, patients with decreasing or undetectable ctDNA levels after 1 cycle of CPI had improved outcomes compared with patients with increasing ctDNA levels (24-mo progression-free survival 72% versus 0%, p < 0.0001). Progression of disease occurred within less than 12 months of starting CPI in all patients with increasing ctDNA levels at C2D1. CONCLUSIONS: Detection of ctDNA before, during, or after 6 months of consolidation CPI is strongly associated with inferior outcomes. Our findings suggest that analysis of ctDNA MRD may enable personalizing the duration of consolidation immunotherapy treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Stanford University, Stanford, California; Stanford Cancer Institute, Stanford University, Stanford, California.
- Community Hospital Oncology Physicians, Community Health Network MD Anderson Comprehensive Cancer Center, Indianapolis, Indiana.
- Division of Hematology/Oncology, IU Simon Comprehensive Cancer Center, Indianapolis, Indiana.
- Division of Oncology-Hematology, Department of Internal Medicine, VA Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska.
- Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, New Jersey.
- Department of Pathology, Stanford University, Stanford, California.
Förderung
- NCI NIH HHS
- NCI
Zitieren
APA
Jun, S., Shukla, N. A., Durm, G., Hui, A. B., Cao, S., Ganti, A. K., Jabbour, S. K., Kunder, C., Alizadeh, A. A., Hanna, N. H., & Diehn, M. (2024). Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC. Journal of Thoracic Oncology, 19(10), 1427-1437. https://doi.org/10.1016/j.jtho.2024.06.024
Vancouver
Jun S, Shukla NA, Durm G, Hui AB, Cao S, Ganti AK, et al. Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC. Journal of Thoracic Oncology. 2024;19(10):1427-1437. doi:10.1016/j.jtho.2024.06.024
BibTeX
@article{Jun2024,
author = {Jun, Soyeong and Shukla, Nikhil A and Durm, Greg and Hui, Angela B and Cao, Sha and Ganti, Apar Kishor and Jabbour, Salma K and Kunder, Christian and Alizadeh, Ash A and Hanna, Nasser H and Diehn, Maximilian},
title = {Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC},
journal = {Journal of Thoracic Oncology},
year = {2024},
volume = {19},
number = {10},
pages = {1427--1437},
doi = {10.1016/j.jtho.2024.06.024}
}
EUVIMED